Clinical Trials Logo

Geographic Atrophy clinical trials

View clinical trials related to Geographic Atrophy.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT03894020 Active, not recruiting - Clinical trials for Macular Degeneration

GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

Start date: January 8, 2019
Phase:
Study type: Observational

An observational study to evaluate the natural progression of dry AMD in genetically defined subjects

NCT ID: NCT03846193 Active, not recruiting - Clinical trials for Macular Degeneration

FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

Start date: December 17, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label first in human Phase I/II multicentre study of GT005 in subjects with Macular Atrophy due to AMD

NCT ID: NCT03845582 Active, not recruiting - Clinical trials for Age Related Macular Degeneration

Phase 3 Study of ALK-001 in Geographic Atrophy

SAGA
Start date: May 7, 2019
Phase: Phase 3
Study type: Interventional

This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). Up to 200 participants will receive ALK-001 while up to 100 participants will receive a placebo.

NCT ID: NCT03815825 Active, not recruiting - Clinical trials for Macular Degeneration

GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Start date: March 4, 2019
Phase: Phase 2
Study type: Interventional

Evaluate the effect of IONIS-FB-LRx on the rate of change of the area of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) measured by fundus autofluorescence (FAF).

NCT ID: NCT03688243 Active, not recruiting - Clinical trials for Dry Macular Degeneration

Non Exudative AMD Imaged With SS-OCT

BIRC-01
Start date: January 18, 2018
Phase:
Study type: Observational

The investigators wish to better understand the role of the choriocapillaris (CC) in the formation and progression of non-exudative in age related macular degeneration (armd) by imaging the retinal pigment epithelium (rpe) and the choroidal microvasculature and by studying their inter-dependence to determine if the loss of the CC could prove useful as an anatomic clinical trial endpoint in future drug trials.

NCT ID: NCT02590692 Active, not recruiting - Geographic Atrophy Clinical Trials

Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD

Start date: February 16, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The Phase I/IIa clinical trial is designed to assess the feasibility of delivery and safety of Human Embryonic Stem Cell-Derived RPE Cells on a parylene membrane (CPCB-RPE1) in patients with advanced, dry age-related macular degeneration. Primary Objective: • To test the safety and tolerability of CPCB-RPE1 during and after subretinal implantation in patients with geographic atrophy with evidence of involvement of the central fovea. Secondary Objective: • To assess visual acuity, visual field, and retinal function after CPCB-RPE1 implantation. Implanted and fellow eyes will be compared post-implantation to assess the ability of the implant to prevent disease progression. Exploratory Objectives: • To assess the feasibility of measuring the change in area of geographic atrophy over time using spectral domain optical coherence tomography or fundus autofluorescence.

NCT ID: NCT00485394 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD)

OMEGA
Start date: June 2007
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to compare the ability of two doses of OT-551 ophthalmic solution and drug-free solution to safely and effectively treat geographic atrophy associated with age-related macular degeneration.